Therapeutic RNA interference (RNAi) has emerged as a promising approach for the treatment of many incurable diseases, including cancer, infectious disease or neurodegenerative disorders. Demonstration of efficacy and safety in animal models is necessary before planning human application. Our group and others have previously shown the potential of this approach for the dominantly inherited neurological disease DYT1 dystonia by achieving potent short-hairpin RNA (shRNA)-mediated silencing of the disease protein, torsinA, in cultured cells. To establish the feasibility of this approach in vivo, we pursued viral delivery of shRNA in two different mouse models. Surprisingly, intrastriatal injections of adeno-associated virus serotype 2/1 (AAV2/1) vectors expressing different shRNAs, whether targeting torsinA expression or mismatched controls, resulted in significant toxicity with progressive weight loss, motor dysfunction and animal demise. Histological analysis showed shRNA-induced neurodegeneration. Toxicity was not observed in animals that received control AAV2/1 encoding no shRNA, and was independent of genotype, occurring in both DYT1 and wild-type animals. Interestingly, the different genetic background of both mouse models influenced toxicity, being earlier and more severe in 129/SvEv than in C57BL/6 mice. In conclusion, our studies demonstrate that expression of shRNA in the mammalian brain can lead to lethal toxicity. Furthermore, the genetic background of rodents modifies their sensitivity to this form of toxicity, a factor that should be taken into consideration in the design of preclinical therapeutic RNAi trials.
INTRODUCTION
RNA interference (RNAi) therapy is emerging as a powerful strategy to silence disease-causing alleles, providing potential treatments for previously incurable diseases. Several laboratories have applied therapeutic RNAi in rodent models of neurodegenerative disease, such as Huntington's disease or Alzheimer's disease, with successful silencing of the disease-linked gene, leading to improvements in disease phenotypes. 1 However, despite the promise of these early preclinical studies, recent reports have raised important concerns on the safety of this therapeutic modality. Adverse effects observed in vivo derive from the saturation of the endogenous microRNA (miRNA) pathway, mostly when highly overexpressing short-hairpin RNAs (shRNAs). Animal demise has been observed when applying shRNAs to nonneural tissues, whereas less dramatic toxicity, likely due to off-targeting effects, was described in the mammalian brain. [2] [3] [4] [5] DYT1, a dominantly inherited neurological disorder with no cure, is the most common form of early-onset inherited dystonia. 6 Nearly all patients with DYT1 have a mutation in the gene TOR1A, which results in a glutamic acid deletion in the protein torsinA (torA(DE)). 7 The current hypothesis of DYT1 pathogenesis posits that torA(DE) acts through a dominant negative effect over torA(wt), leading to a total loss of torA function. [8] [9] [10] Studies completed in cultured cells by our group and others have shown that RNAi-mediated allele-specific silencing of torA(DE) prevents and reverses DYT1-associated phenotypes, thus providing potential therapeutic efficacy. 8, 10, 11 Furthermore, non-specific silencing of both torA alleles is detrimental 10 and, as a result, could be used to trigger or worsen the phenotype of DYT1 mice. Here, we designed experiments to establish the therapeutic efficacy and safety of RNAi-mediated allele-specific silencing of torA(DE) in a transgenic mouse model of DYT1 dystonia. In parallel, we aimed to trigger a motor phenotype in DYT1 knock-in (KI) mice through non-specific silencing of torA.
Unexpectedly, we detected lethal toxicity caused by striatal expression of U6shRNA in both DYT1 mouse models, an outcome independent of the DYT1 mutation as it was also observed in wild-type mice. Interestingly, the genetic background influenced the sensitivity of mice to this toxicity, underscoring the relevance of model selection for therapeutic studies.
RESULTS

Striatal injection of AAV2/1 shRNAs causes lethal toxicity in DYT1 mouse models
We used two different DYT1 mouse models for our studies. The first is a recently developed transgenic model expressing either a human torA(DE) (D9.hTorA(DE) mice) or a torA(WT) (D9.hTorA(WT) mice) under the control of a striatal-specific DARPP-32 (D9) promoter 12 and maintained on a C57BL/6 background. Using these mice, we aimed to demonstrate potent allele-specific silencing of human torA(DE). To trigger a motor phenotype through non-specific silencing of torA, we selected mice in which the human DYT1 mutation has been knocked into the murine tor1A gene (DYT1 KI mice). This model was maintained on a 129/SvEv background. As delivery vehicle, we used recombinant adeno-associated virus serotype 2/1 (AAV2/1) with a green fluorescent protein (GFP) reporter gene to deliver different U6shRNAs to the striatum of both DYT1 KI mice, D9.hTorA(WT or DE) mice and their wild-type littermates (Figures 1a and b ).
To investigate whether non-selective suppression of torsinA in the striatum would cause motor dysfunction in adult mice, we performed intrastriatal injections of an U6shRNA that efficiently suppresses expression of both wild-type and mutant murine torsinA (AAV2/ 1.GFP.U6shTorA) in 2.5-6-month-old DYT1 KI mice and in their wild-type littermates. Control vectors included AAV2/1.GFP with no shRNA, a missense hairpin (U6shMis) or U6shHtorA(DE), which targets human but not murine torA(DE), thus acting as a second missense control. Unexpectedly, 2-5 weeks after injection, we found progressive weight loss and significant lethality of both experimental and control shRNAs, whereas no death was observed in mice receiving virus expressing no shRNA ( Figure 1c ). shRNAs showed varying levels of toxicity, with mice injected with the U6shTorA hairpin showing markedly lower mortality rates than either U6shHtorA(DE) or U6shMis. The presence of the DYT1 mutation did not influence this effect.
In a parallel set of experiments, D9.hTorA(WT) transgenic mice were used to test the efficacy of the therapeutic shRNA, U6shHtor-A(DE), to achieve allele-specific silencing of human torA(DE) in vivo. Although the full characterization of these mice will be published elsewhere (Ehrlich et al., manuscript in preparation), we detected striatal expression of the transgene by western blot analysis and immunostaining that would allow us to measure silencing (data not shown). Mice were injected in the striatum with AAV2/ 1.GFP encoding either the therapeutic construct (U6shHtorA(DE)), a missense control shRNA (U6shMis), or a virus expressing no shRNA. Mortality in the first 5 weeks after injection was significantly lower than in DYT1 KI mice, even though they received the same viral preps. We observed delayed mortality in D9.hTorA(WT or DE) and in nontransgenic littermates injected with U6shhTorA(DE) or U6shMis, with no toxicity in mice injected with AAV2/1.GFP ( Figure 1d ). The differences in the magnitude and timing of mortality between DYT1 KI and transgenic mice were observed regardless of genotype, indicating that they are a consequence of the genetic background of mice. To eliminate the potential confounding factor introduced by the DYT1 mutation and transgene expression, we looked specifically at control mice (that is, non-transgenic, non-KI), detecting significant differences in mortality between 129/SvEv and C57BL/6 mice that received the same U6shHtorA(DE)-and U6shMis-encoding viral preps (see control mice in Figures 1c and d) .
Abnormal motor function caused by striatal expression of U6shRNA
Baseline behavior analysis of motor function was performed in both DYT1 KI and D9.hTorA(WT or DE) mice before injection. A comparison of results from both open-field behavior and rotarod analysis revealed no significant changes in performance between wild-type and KI mice (not shown). Owing to the high levels of mortality observed in DYT1 KI mice, post-injection behavior analysis could not be completed.
Due to the lower and delayed mortality observed in D9.hTorA mice, post-injection behavior could be completed in surviving animals. We recorded their performance on a rotarod and open field before and at 
U6shRNA induces striatal toxicity
To determine the effects of these toxic U6shRNAs at the tissue level, we harvested the brains from D9.hTorA and control mice 6-9 months after injection. A survey of striatal sections revealed that multiple U6shRNA-injected mouse brains exhibited enlarged ventricles ( Figure 3a ), indicating striatal atrophy. Immunohistochemical analysis was completed to detect DARPP-32 expression, a marker of striatal medium spiny neurons. We observed a loss of DARPP-32 signal and reduced GFP signal in the transduced striatum of mice injected with either of the U6shRNAs, but not in the brains that received control virus (Figure 3b ), suggesting loss of transduced neurons. Investigation of DARPP-32 levels in DYT1 KI mice revealed a similar pattern suggesting neuronal loss (not shown). The regions transduced by the shRNA-encoding vectors, but not with control virus, also demonstrated decreased cresyl violet staining, further suggesting neurodegeneration ( Figure 3c ). Taken together, these results suggest that expression of U6shRNAs caused the loss of striatal medial spiny neurons. Furthermore, immunohistochemical staining for a glial marker, glial fibrillary acidic protein, demonstrated astroglial activation in areas transduced by the toxic U6shRNA, but not with control AAV2/1 (Supplementary Figure 1 ). As described for the DARPP-32 staining, reduced GFP signal was observed together with enhanced glial fibrillary acidic protein staining, suggesting loss of transduced neurons and replacement by astroglial cells. However, we did not observe differences in Iba-1 expression (not shown), a marker of microglial activation. 4 
Analysis of the endogenous miRNA pathway
To determine whether significant variation in miRNA expression or processing underlie the different susceptibility of both strains to U6shRNA-induced toxicity, we analyzed the expression of two candidate miRNAs and key components of the miRNA pathway in the striatal tissue obtained from control animals from both mouse strains. Expression and processing of a ubiquitous (miR30a) and a neuronalspecific miRNA (miR9) ( Figure 4a ) did not differ between both strains. We then measured expression levels of key components of the miRNA pathway by western blot analysis, demonstrating similar levels of Ago2 in both strains and a non-significant trend towards lower levels of exportin5 2 in 129/SvEv mice ( Figure 4b ). Similar results were obtained in the cortical tissue obtained from the same animals (not shown). We next asked whether the expression of toxic shRNAs influences the levels of miRNA expression and processing. For these experiments, we used C57BL/6 mice because of their enhanced survival after the injections. We found that levels of unprocessed pre-miRNA were not significantly changed by the overexpression of shRNAs, but those of the mature strand were highly variable with a tendency to be increased ( Figure 5a ). Interestingly, although exportin5 expression was mostly unchanged, the levels of Ago2 were inversely correlated with the increase in mature miRNA observed by northern blotting for each animal (Figure 5b ). Quantitative reverse transcription-PCR for mature miR9 in an independent set of animals confirmed the northern blot findings (Figure 5c ). Levels of exportin5, Ago2, unprocessed pre-miRNA and mature miRNA in non-transduced cortical areas of the same animals were not changed (not shown). These observations could derive from an effect of shRNAs on the endogenous miRNA pathway, or simply reflect variable cell death and astroglial reaction caused by toxic shRNAs.
DISCUSSION
In this study, we demonstrate lethal toxicity caused by the application of therapeutic RNAi-mediating vectors to mouse models of In all three genotypes, mice injected with either U6shMis or U6shHtorA(DE) showed increased motor activity at both 6-8 weeks and 14-16 weeks after injection that was not observed in mice injected with no shRNA. (b) Motor coordination as measured using a rotarod apparatus over 3 days showing latency to fall (mean ± s.e.m. for trials 1-3 for each group per day) (*Po0.05, **Po0.01, *** Po0.001). In all three genotypes, mice injected with either shMis or shHtorA(DE) showed reduced motor coordination at both 6-8 weeks and 14-16 weeks after injection when compared with no shRNA controls. r.p.m., revolutions per minute.
neurological disease. Our studies show that pol-III-transcribed shRNAs applied to the murine striatum can cause neuronal loss, behavioral dysfunction and animal demise. Furthermore, the genetic background of animals used modifies susceptibility to this adverse effect, indicating that this factor needs to be considered and controlled when designing RNAi trials. This study adds to our current knowledge of therapeutic gene silencing.
RNAi therapy has shown great promise towards the treatment of neurological disorders. Therapeutic trials have been completed or are underway for treatment of several non-neurological diseases, and preclinical studies in different animal models of various neurological diseases have been reported. 1 The clinical, genetic and biological characteristics of DYT1 dystonia make it an optimal disease model to explore the potential of therapeutic RNAi. Several studies in cellular models of DYT1 have paved the road for trials in vivo. 8, 10, 11, 13 The shRNAs used for this study were previously tested in cultured mammalian neurons demonstrating efficacy and, most importantly, no evidence of toxicity. 8 Thus, the results of this study indicate that lack of cell death or inflammatory responses in cultured cells does not translate into safety of the targeting sequence in vivo, stressing the need to evaluate the presence of adverse effects in the appropriate model.
A landmark study by Kay and colleagues, 2 in which they encountered animal demise when targeting genes in mouse hepatocytes, brought general attention to the potential toxicity of shRNAs in non-nervous tissues. Similar to our study, this occurred in wild-type mice. Most trials in mouse models of neurological disease used viral delivery of shRNAs and focused mainly on the demonstration of efficacy. 1 However, hints of potential toxicity by shRNAs were already observed. For instance, when targeting the mutant huntingtin in Huntington's disease transgenic mice, Rodriguez-Lebron et al. 14 detected toxicity using a shRNA previously shown to be effective in cultured cells. Furthermore, Davidson and colleagues 15 found that wild-type mice injected with one of their therapeutic shRNAs for Huntington's disease showed mild and transient phenotypical worsening. The same group demonstrated toxicity with microglial activation upon intrastriatal delivery of shRNAs in a mouse model of Huntington's disease, believed to derive from off-targeting effects. 4 More recently, AAV-mediated expression of shRNAs has been shown to cause neuronal death. 16 Our study further extends these reports by demonstrating striatal atrophy with associated behavioral dysfunction and death. It is important to emphasize that we encountered the same levels of toxicity in wild-type than in DYT1 mice. This has important implications for preclinical tolerability studies for optimizing shRNAs to minimize induced toxicity, regardless of the model. Even more, because these toxic constructs caused cell loss in non-disease mice, it is possible that some diseases characterized by neurodegeneration could be accelerated by the application of these vectors. Collectively, these studies strongly suggest that the first generation of vectors, based on highly expressed pol-III-driven shRNAs, are not optimal for therapeutic development and should be optimized and carefully evaluated for potential toxicity. Different strategies have been developed to abolish the toxic side effects of highly expressed shRNAs, such as decreasing levels of expression by placing the shRNA under a different pol-III promoter like H1 or a pol-II promoter, or by enhancing processing efficiency of the targeting sequence by embedding it in an miRNA backbone. 4, 5, 17 Similar modifications should be adapted to advance in the development of therapeutic RNAi-based constructs for DYT1 dystonia and other neurological diseases.
Whereas several mechanisms can potentially cause shRNA-derived adverse effects, emerging evidence suggests that dysfunction of the endogenous miRNA pathway due to saturation from exogenous constructs is the most likely mechanism. 2, 18 Overall, these studies suggest that a very high overexpression of shRNAs from the highly active U6 promoter might cause toxicity by saturating the miRNA pathway. Our different shRNA constructs were expressed from the U6 promoter and, at least in cultured cells, they silence their targets very potently, suggesting high levels of overexpression. Here, we show that AAV2/1 delivery of U6shRNAs to the striatum can induce lethal toxicity in mice, with the loss of neurons transduced by different U6shRNA vectors. Although animal demise from fulminant liver failure is predictable, death caused by the loss of a limited region of the striatum is not as intuitive. However, McManus and colleagues 19 recently demonstrated that dysfunction of the miRNA pathway caused by the conditional deletion of dicer in postnatal murine striatal medium spiny neurons results in progressive motor dysfunction, reduced brain size, wasting and death at 10-12 weeks of age. Thus, dysfunction of the miRNA pathway in striatal neurons can cause progressive motor dysfunction and death. Why toxic shRNAs led to increased locomotor activity is unclear, but it could perhaps be due to differences in transduction efficiency or susceptibility to this toxicity between medium spiny neurons that participate in the direct or indirect pathway.
An interesting and unexpected result of our studies is the different susceptibility to shRNA-induced adverse effects between two commonly used mouse genetic backgrounds, which exhibit significant differences at the level of gene expression in the brain tissue. 20 We speculated that the basis of this finding could be different efficiency in miRNA processing between striatal neurons of both strains, and completed studies that show a trend towards lower levels of exportin5 expression in the more susceptible strain, although the significance of this finding is unclear. The expression of toxic shRNAs did not alter exportin5 levels, but led to variability in endogenous Ago2 and miR9 expression. Interestingly, levels of Ago2 inversely correlated with the accumulation of mature miRNAs. In their initial report of liver toxicity, Grimm et al. 2 explored the underlying cause, reaching the conclusion that saturation of the putative rate-limiting step of this pathway, the nuclear export of pre-miRNAs by exportin5, was the responsible event. However, the same group recently identified Ago2 as a rate-limiting determinant of RNAi efficacy, toxicity and persistence. 18 In light of this report, it is tempting to speculate that variations in Ago2 levels lead to impaired processing of endogenous miRNAs and are implicated in shRNA toxicity in neurons. Why Ago2 levels are variable upon the expression of toxic shRNAs and why this correlates with higher miR9 levels is unclear, and might simply reflect the changes in tissue architecture caused by neuronal degeneration and glial reaction. Furthermore, how reduced Ago2 expression would affect miR9 levels is unclear. Whether differences in exportin5 and/or Ago2 expression or function between 129/SvEv and C57BL/6 mice are responsible for their different susceptibility to the toxic effects of shRNAs remain to be proven. Manipulation of exportin5 and Ago2 expression upon the neuronal application of toxic shRNAs would help test this hypothesis, regardless of what the final cause for these differences proves to be, although researchers should carefully consider the background of the animal model used for preclinical RNAi therapy trials. 129/SvEv mice might be an optimal strain when aiming to exclude shRNA-induced toxicity in preclinical studies.
In summary, this study demonstrates the presence of lethal toxicity caused by striatal expression of shRNAs and illustrates differences derived from the genetic background of the model used for therapeutic silencing studies. These findings have important implications for the design of preclinical therapeutic RNAi trials in models of human neurological disease.
MATERIALS AND METHODS Animals
DYT1 KI mice, generated by Dauer and colleagues, 21 were maintained on a 129/SvEv background. D9 transgenic mice that express one copy of either human TorA(DE) (D9.hTorA(E) mice) or TorA(WT) (D9.hTorA(WT) mice) under the control of a DARPP-32 promoter were maintained on a C57BL/6 background. The generation and characterization of this model will be described elsewhere (Ehrlich et al, manuscript in preparation). Mice were housed in temperature-controlled rooms with 12-h light and dark cycles. Food and water were provided ad libitum. All experimental protocols were approved by the University of Iowa Animal Care and Use Committee.
Viral expression vectors
Recombinant AAV2/1 vectors expressing shRNAs were generated as described previously 4 by the Gene Transfer Core at the University of Iowa. In brief, U6shRNA expression cassettes were cloned into AAV2/1 shuttle plasmids, and the AAV2/1 recombinant virus was generated using a well-established calcium phosphate transfection method. 22 Reverse transcription-PCR was use to determine viral titers with concentrations between 5Â10 12 and 2.5Â10 13 vg per ml. The targeting sequences used in this study were previously reported by Gonzalez-Alegre et al., 8 although their identification names have been modified for simplicity as follows: U6shTorA in this study corresponds to shTAcom in Gonzalez-Alegre et al., 8 U6shHtorA(DE) to shTAmut5 and U6shMis to shTAmis.
Striatal injections
Three-to-six-month-old mice were anesthetized with ketamine/xylazine and placed in a David Kopf stereotaxic frame (Model 900, David Kopf Instruments, Tujunga, CA, USA). After a sterile technique, bilateral striatal injections of 2 ml (100 nl min À1 ) of AAV2/1 were performed through a burr hole, using a Hamilton syringe and programmable UltraMicroPumpII (World Precision Instruments, Sarasota, FL, USA) at the following coordinates with respect to the bregma: 0.9 mm anterior, 1.8 mm lateral to the midline, 2.8 mm ventral to the dura. Once completed, the needle was raised 0.3 mm and then left in for 5 additional minutes to allow diffusion and to avoid spread of the solution along the pipette track.
Behavioral analysis
Rotarod performance. In brief, mice were first acclimated to the rotarod (model 47 600 Ugo Basile, Milan, Italy) for 3 min at a steady rate of 4 r.p.m. (revolutions per minute) and then at an accelerating rate from 4 to 16 r.p.m. over 2 min. Mice were tested for 3 days with 3 trials per day on a rotarod set to accelerate from 4 to 40 r.p.m. over a period of 5 min. Latency to fall was recorded on each day with a maximum cutoff at 500 s. Mice that rode the rotating rod for three complete revolutions without moving forward were removed because of inactivity. Mice that were unable to stay on the apparatus for at least 120 s were not placed into injection groups.
Open field. After acclimation, four mice were recorded simultaneously by placing them in an open-field arena with four separate 25 cmÂ25 cm fields. We Figure 5 Analysis of the microRNA pathway in transduced striatum. The striata of animals injected with vectors encoding shMis, shHtorA(DE) or control virus were extracted. (a) The right striatum was used for northern blot analysis of miR9 expression and processing by detecting pre-miR9 and mature miR9. It must be noted that both bands are from the same blot, but with different exposure. U6 is shown as a loading control. (b) The left striatum of the same animal was used for western blot analysis to detect expression of exportin5, Ago2 and a-tubulin as a loading control. Samples for the northern and western blot analyses shown in the top and bottom panels, respectively, were run in the same order. (c) Q-RT-PCR of miR9, normalized to U6 expression, in striata expressing AAV2/1.eGFP (reference), AAV2/1.eGFP.U6shMis or AAV2/1.eGFP.U6shHtorA(DE). Differences were non-significant.
used an automated tracking system (Viewpoint, Videotrak, Lyon, France) to collect and analyze data (distance traveled) in 5-min bins for 60 min.
Immunohistochemical analyses
Mice were killed 6-9 months after injection, perfused transcardially with ice-cold 0.9% NaCl and then fixed with 4% paraformaldehyde. The brains were excised, postfixed overnight and then stored in a 30% sucrose solution at 4 1C until ready for use. Immunohistochemical analysis was performed as described previously. 5 In brief, free floating coronal sections of the brain (40 mm) were incubated with antibodies to detect DARPP-32 (Cell Signaling Technology, Danvers, MA, USA) or Iba-1 (Wako Chemicals USA, Richmond, VA, USA) for 24 h at room temperature. Brain sections were next incubated in a biotinylated secondary antibody (1:200) for 1 h, placed in ABC reagent (both from Vector Laboratories, Burlingame, CA, USA) and developed in a 3-3¢ diaminobenzidine solution. Finally, sections were mounted onto SuperFrost Plus slides and coverslipped with Permount (Thermo-Fisher Scientific, Waltham, MA, USA). GFP autofluorescence of transduced regions were captured before staining and DARPP-32 images after using an Olympus SZX12 fluorescent stereoscope with an Olympus DP70 camera (Olympus America, Center Valley, PA, USA) using accompanying software. For indirect immunofluorescence, sections were incubated with Cy3-conjugated monoclonal glial fibrillary acidic protein antibodies (Sigma, St Louis, MO, USA) and processed as described previously 8 before visualization. Cresyl violet staining was completed following standard protocols.
Molecular studies
RNA isolation. Mice were perfused transcardially with ice-cold 0.9% NaCl, and then their brains were excised and placed in a matrix and cut into 1-mm sections. Transduced striatal regions were surgically removed, weighed and then placed in RNA later (Qiagen, Valencia, CA, USA) and stored at À80 1C until ready for use. RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions and resuspended in Ultrapure DNase/RNase-free distilled water (Invitrogen). RNA quality and concentration were assessed using a NanoDrop ND-1000 spectrophotometer (Thermo-Fisher Scientific).
Northern blotting. Small-transcript northern blots were performed as described previously. 23 In brief, 5 mg of total RNA was run on a 15% PAGE-UREA gel, transferred to a Hybond NX nylon membrane (Amersham Pharmacia, Piscataway, NJ, USA) and then cross-linked with 0.16 M N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride in 127 mM 1-methylimidazole (pH 8) at 60 1C for 1 h. Membranes were then hybridized with g[32P] ATP-labeled oligonucleotides at 35 1C overnight, washed in 2Â SSC, exposed to a phosphoimager screen and quantified on a Molecular Dynamics STORM PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). The probe sequences used were as follows: U6: 5¢-CGTTCCAATTTTA GTATATGTGCTGCC-3¢, miR9: 5¢-TCATACAGCTAGATAACCAAAGA-3¢, miR30a: 5¢-CTTCCAGTCGAGGATGTTTACA-3¢.
Quantitative reverse transcription-PCR. For relative miRNA expression, 350 ng RNA was reverse transcribed using the TaqMan mRNA Reverse-Transcription Kit with Megaplex RT Primer Rodent Pool A (Applied Biosystems, Foster City, CA, USA) and then the diluted reverse-transcription product (1:10) was used to determine levels of mature miR9 by TaqMan miRNA Assays (Applied Biosystems) using the manufacturer's protocols and normalized to U6 small nuclear RNA. Fold changes were determined using the DDCT method, and calibrated to the AAV2/1.eGFP-injected striata.
Western blotting. Mice were perfused transcardially with ice-cold 0.9% NaCl, and then the transduced striatum was excised, weighed and snap frozen in liquid nitrogen and stored at À80 1C until ready for use. The brains were homogenized and suspended in RIPA lysis buffer. Western blotting was performed as described previously. 13 In brief, protein samples were run on a 12% SDS-PAGE gel, transferred to a nitrocellulose membrane and then probed with exportin5, Argonaut 2 (Abcam, Cambridge, UK) and a-tubulin antibodies (Sigma). Blots were incubated using a Western Lighting Plus-ECL kit (PerkinElmer, Wellesley, MA, USA) and developed using Kodak BioMax MR Film (Kodak, Rochester, NY, USA).
Blot quantification. We quantified western and northern blot signals as described previously 13 using U6 and a-tubulin signals as loading controls for normalization, and expressing the results as a percentage of the resulting signals compared with the control lanes.
Statistical analysis
All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA). Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using the log-rank test. A linear mixed model for repeated measures was used to analyze the open field and rotarod data. A probability value o0.05 was considered statistically significant.
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